Evidence map›Paper›PMID 38425459›Full record

ArticleGynecologic oncology reports2024

Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.

Panagiotis A Konstantinopoulos, Niya Xiong, Carolyn Krasner, Joyce F Liu, Hannah Sawyer, Madeline Polak, Hope Needham, Megan Geddes, Lani Koppermann, Meghan Shea and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Panagiotis A KonstantinopoulosDana-Farber Cancer Institute, Boston, MA, USA.
Niya XiongDana-Farber Cancer Institute, Boston, MA, USA.
Carolyn KrasnerDana-Farber Cancer Institute, Boston, MA, USA.
Joyce F LiuDana-Farber Cancer Institute, Boston, MA, USA.
Hannah SawyerDana-Farber Cancer Institute, Boston, MA, USA.
Madeline PolakDana-Farber Cancer Institute, Boston, MA, USA.
Hope NeedhamDana-Farber Cancer Institute, Boston, MA, USA.
Megan GeddesDana-Farber Cancer Institute, Boston, MA, USA.
Lani KoppermannDana-Farber Cancer Institute, Boston, MA, USA.
Meghan SheaBeth Israel Deaconess Medical Center, Boston, MA, USA.
Cesar CastroMassachusetts General Hospital, Boston, MA, USA.
Su-Chun ChengDana-Farber Cancer Institute, Boston, MA, USA.
Ursula A MatulonisDana-Farber Cancer Institute, Boston, MA, USA.
Elizabeth K LeeDana-Farber Cancer Institute, Boston, MA, USA.
Dana-Farber Cancer Institute · USBeth Israel Deaconess Medical Center · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several lines of preclinical evidence indicate that combining PI3K and CDK4/6 inhibitors may further enhance the efficacy of hormonal therapy by overcoming

Indexed as

AbemaciclibAromatase inhibitionCDK4/6 inhibitionEndometrial cancerLY3023414PI3K inhibition

Identifiers

PMID38425459
PMCPMC10901901
OpenAlexW4392055484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.